Mayne Pharma Group Limited
MAYNF
$3.29
-$0.23-6.54%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.32M | -8.56M | -34.16M | -34.09M | -22.99M |
| Total Depreciation and Amortization | 10.32M | 10.61M | 10.52M | 10.50M | 11.69M |
| Total Amortization of Deferred Charges | 873.80K | 898.50K | 750.60K | 749.00K | 500.80K |
| Total Other Non-Cash Items | -7.48M | -7.69M | 25.59M | 25.54M | 7.90M |
| Change in Net Operating Assets | 363.00K | 373.20K | 1.72M | 1.72M | -6.46M |
| Cash from Operations | -4.25M | -4.37M | 4.42M | 4.41M | -9.36M |
| Capital Expenditure | -2.24M | -2.30M | -1.57M | -1.57M | -1.03M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 2.26M | 2.25M | -- |
| Other Investing Activities | -12.42M | -12.77M | -5.22M | -5.21M | 22.93M |
| Cash from Investing | -14.66M | -15.07M | -4.53M | -4.52M | 21.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.03M | -1.03M | -934.50K | -934.50K | -6.40M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | -5.47M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 903.00K | 903.00K | 1.11M | 1.11M | 1.76M |
| Cash from Financing | -84.70K | -87.10K | 115.70K | 115.40K | -6.58M |
| Foreign Exchange rate Adjustments | 627.50K | 645.30K | 272.50K | 271.90K | -545.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.36M | -18.88M | 277.10K | 276.50K | 5.41M |